US Patent Issued to Sangamo Therapeutics on March 3 for "Engineering AAV" (California Inventors)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,565,685, issued on March 3, was assigned to Sangamo Therapeutics Inc. (Richmond, Calif.).

"Engineering AAV" was invented by Kyle McGovern (Richmond, Calif.) and David S. Ojala (Richmond, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof."

The patent was filed on April 9, 2024, under Application No. 18/630,996.

*For further information, including...